Homocysteine: An emergent cardiovascular risk factor?

European Journal of Clinical Investigation

Volumn 30, Issue 9, 2000, Pages 754-762

  Medina, ^a   Amores Sanchez ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Cardiovascular disease; Cobalamine; Folate; Homocysteine

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLCYSTEINE; ADENOSYLHOMOCYSTEINASE; CYANOCOBALAMIN; CYSTEINE; FOLIC ACID; HOMOCYSTEINE; METHIONINE; METHIONINE SYNTHASE; METHYL GROUP; PYRIDOXINE; S ADENOSYLMETHIONINE; TETRAHYDROFOLIC ACID; TRANSFER RNA;

AGE; AMINO ACID BLOOD LEVEL; AMINO ACID SYNTHESIS; CARDIOVASCULAR DISEASE; DISEASE MARKER; GENETIC PREDISPOSITION; GEOGRAPHIC DISTRIBUTION; HUMAN; HYPERHOMOCYSTEINEMIA; METHYLATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE;

CARDIOVASCULAR DISEASES; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; RISK FACTORS;

EID: 0033821577     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00691.x     Document Type: Review

References (80)

1. Biological markers as predictors of cardiovascular disease
2. Oxidative damage and defense
3. Hiperhomocisteinemia, un nuevo marcador de riesgo vascular: Territorios vasculares afectados, papel en la patogenesis de la arteriosclerosis y la trombosis y tratamiento
4. Homocysteine and cardiovascular disease
5. Homocysteine and vitamins in cardiovascular disease
6. Methionine metabolism in mammals
7. A novel pathway for the conversion of homocysteine to methionine in eukaryotes
8. Synthesis of homocysteine thiolactone by methionyl-tRNA synthetase in cultured mammalian cells
9. Total homocysteine in plasma or serum: Methods and clinical applications
10. Characterization of homocysteine metabolism in the rat kidney
11. Homocysteine and vascular disease
12. No net renal extraction of homocysteine in fasting humans
13. Methionine synthase inactivation by nitrous oxide during methionine loading of normal human fibroblasts. Homocysteine remethylation as determinant of enzyme inactivation and homocysteine export
14. Diagnosis of cobalamin deficiency. 1. Usefulness of serum methylmalonic acid and total homocysteine concentrations
15. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry
16. Effect of vitamin B-6 deficiency on fasting plasma homocysteine concentrations
17. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease - Effects of pyridoxine and folic acid treatment
18. Homocystinuria: Metabolic studies on 3 patients
19. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drug therapy
20. The identification of homocysteine in the urine
21. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland
22. Inherited disorders of vitamin-B12 utilization
23. Homocystinuria: An enzymatic defect
24. Homocysteine and vascular disease
25. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis
26. Homocysteine theory of arteriosclerosis
27. The pathogenesis of coronary artery disease. A possible role for methionine metabolism
28. Hyperhomocysteinemia: An independent risk factor for vascular disease
29. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes
30. Serum folate and risk of fatal coronary heart disease
31. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project
32. Plasma homocysteine levels and mortality in patients with coronary artery disease
33. Hyperhomocysteinemia and recurrent spontaneous abortion or abruptio placentae
34. Maternal hyper-homocysteinemia: A risk factor for neural-tube defects?
35. S-Adenosylmethionine (ademethionine) in psychiatric disorders: Historical perspective and current status
36. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease?
37. Perturbation of homocysteine metabolism by pharmacological agents in experimental and clinical use
38. Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine
39. Plasma homocysteine in children with acute lymphoblastic leukemia. Changes during a chemotherapeutic regimen including methotrexate
40. Is absence of atheroma in Down syndrome due to decreased homocysteine levels?
41. Radioenzymic determination of homocysteine in plasma and urine
42. Quantitation of total homocysteine, total cysteine and methionine in normal serum and urine using capillary gas chromatographymass spectrometry
43. High-performance liquid chromatographic method with fluorescence detection for the determination of total homocyst(e)ine in plasma
44. Analysis of hepatic reduced glutathione, cysteine and homocysteine by cation-exchange high-performance liquid chromatography with electrochemical detection
45. Fully automated assay for total homocysteine, cysteine, cysteineglycine, glutathione, cysteamine, and 2-mercaptopropionylglycine in plasma and urine
46. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer
47. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum
48. Method comparison for total plasma homocysteine between the Abbott IMx analyzer and an HPLC assay with internal standardization
49. Determination of total homocysteine
50. Folate and vitamin B-6 from diet and supplements in relation to risk of coronary heart disease among women
51. Plasma homocysteine and cardiovascular disease mortality
52. The natural history of homocystinuria due to cystathionine beta-synthase deficiency
53. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase
54. Increase in total plasma homocysteine concentration after cardiac transplantation
55. High homocysteine, low folate, and low vitamin B6 concentrations: Prevalent risk factors for vascular disease in heart transplant recipients
56. Hyperhomocysteinaemia in heart transplant recipients
57. Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients
58. Homocysteine and lipid metabolism in atherogenesis: Effect of homocysteine thiolactonyl derivatives, thioretinaco and thioretinamide
59. Homocysteinemia: Vascular injury and arterial thrombosis
60. Homocysteine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis
61. Developmental mechanisms underlying pathology of arteries
62. The pathogenesis of atherosclerosis: A perspective for the 1990s
63. Homocysteine catabolism: Levels of 3 enzymes in cultured human vascular endothelium and their relevance to vascular disease
64. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis
65. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine
66. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase
67. Stimulation of endothelial nitric oxide production by homocysteine
68. Homocysteine and thrombotic disease
69. Homocysteine and other sulfhydryl compounds enhances the binding of lipoprotein (a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism
70. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine
71. Lowered antitrombina III activity and other clotting changes in homocystinuria. Effects of a pyridoxine-folate regimen
72. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells
73. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells
74. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor
75. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells
76. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator
77. Biological chemistry of thiols in the vasculature and in vascular-related disease
78. Characterization of the stress-inducing effects of homocysteine
79. N-Acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein levels
80. Folate and cardiovascular disease. Why we need a trial now